Hybio Pharmaceutical Co., Ltd. (300199.SZ)
CNY 13.79
(-0.93%)
CNY 13.79
(-0.93%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 680.36 Million CNY | -21.77% |
| 2022 | 631.7 Million CNY | 1.7% |
| 2021 | 621.12 Million CNY | -5.35% |
| 2020 | 656.26 Million CNY | -28.98% |
| 2019 | 924.09 Million CNY | 9.87% |
| 2018 | 841.08 Million CNY | 35.68% |
| 2017 | 619.91 Million CNY | 90.63% |
| 2016 | 325.18 Million CNY | 29.63% |
| 2015 | 250.86 Million CNY | 56.52% |
| 2014 | 160.27 Million CNY | 35.95% |
| 2013 | 117.89 Million CNY | 26.8% |
| 2012 | 92.97 Million CNY | 49.84% |
| 2011 | 62.04 Million CNY | 61.19% |
| 2010 | 38.49 Million CNY | 27.76% |
| 2009 | 30.13 Million CNY | 18.23% |
| 2008 | 25.48 Million CNY | 56.2% |
| 2007 | 16.31 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 68.23 Million CNY | -45.97% |
| 2024 Q2 | 58.56 Million CNY | -14.17% |
| 2024 Q3 | 61.33 Million CNY | 59.44% |
| 2023 Q3 | 114.16 Million CNY | -24.02% |
| 2023 FY | 494.18 Million CNY | -21.77% |
| 2023 Q2 | 150.25 Million CNY | 45.22% |
| 2023 Q4 | 126.3 Million CNY | 10.63% |
| 2023 Q1 | 103.46 Million CNY | -47.56% |
| 2022 Q1 | 89.2 Million CNY | -52.33% |
| 2022 Q4 | 197.3 Million CNY | 9.0% |
| 2022 Q3 | 181.01 Million CNY | 10.25% |
| 2022 FY | 631.7 Million CNY | 1.7% |
| 2022 Q2 | 164.18 Million CNY | 84.06% |
| 2021 Q3 | 173.57 Million CNY | 2.77% |
| 2021 Q1 | 91.55 Million CNY | -58.91% |
| 2021 Q2 | 168.89 Million CNY | 84.48% |
| 2021 Q4 | 187.1 Million CNY | 7.8% |
| 2021 FY | 621.12 Million CNY | -5.35% |
| 2020 FY | 656.26 Million CNY | -28.98% |
| 2020 Q4 | 222.82 Million CNY | 13.32% |
| 2020 Q3 | 196.62 Million CNY | 43.52% |
| 2020 Q2 | 137 Million CNY | 37.25% |
| 2020 Q1 | 99.82 Million CNY | -76.7% |
| 2019 Q4 | 428.41 Million CNY | 92.63% |
| 2019 FY | 924.09 Million CNY | 9.87% |
| 2019 Q1 | 101.93 Million CNY | -72.83% |
| 2019 Q2 | 171.33 Million CNY | 68.08% |
| 2019 Q3 | 222.41 Million CNY | 29.81% |
| 2018 Q2 | 202.12 Million CNY | 56.82% |
| 2018 Q1 | 128.89 Million CNY | -57.83% |
| 2018 FY | 841.08 Million CNY | 35.68% |
| 2018 Q4 | 375.25 Million CNY | 178.35% |
| 2018 Q3 | 134.81 Million CNY | -33.3% |
| 2017 Q3 | 117.5 Million CNY | -14.59% |
| 2017 FY | 619.91 Million CNY | 90.63% |
| 2017 Q2 | 137.57 Million CNY | 132.46% |
| 2017 Q1 | 59.18 Million CNY | -40.34% |
| 2017 Q4 | 305.64 Million CNY | 160.12% |
| 2016 Q3 | 88.41 Million CNY | 6.72% |
| 2016 FY | 325.18 Million CNY | 29.63% |
| 2016 Q2 | 82.85 Million CNY | 51.44% |
| 2016 Q1 | 54.71 Million CNY | -39.14% |
| 2016 Q4 | 99.2 Million CNY | 12.2% |
| 2015 Q3 | 58.46 Million CNY | 1.61% |
| 2015 Q4 | 89.9 Million CNY | 53.76% |
| 2015 Q1 | 44.95 Million CNY | 6.55% |
| 2015 Q2 | 57.54 Million CNY | 28.01% |
| 2015 FY | 250.86 Million CNY | 56.52% |
| 2014 Q3 | 43.61 Million CNY | 9.06% |
| 2014 Q4 | 42.18 Million CNY | -3.28% |
| 2014 Q2 | 39.99 Million CNY | 16.02% |
| 2014 Q1 | 34.47 Million CNY | -1.67% |
| 2014 FY | 160.27 Million CNY | 35.95% |
| 2013 Q3 | 31.66 Million CNY | 0.9% |
| 2013 Q1 | 19.78 Million CNY | -29.85% |
| 2013 Q2 | 31.38 Million CNY | 58.64% |
| 2013 Q4 | 35.05 Million CNY | 10.7% |
| 2013 FY | 117.89 Million CNY | 26.8% |
| 2012 Q4 | 28.2 Million CNY | 34.02% |
| 2012 Q1 | 19.51 Million CNY | 34.03% |
| 2012 FY | 92.97 Million CNY | 49.84% |
| 2012 Q2 | 24.21 Million CNY | 24.09% |
| 2012 Q3 | 21.04 Million CNY | -13.11% |
| 2011 Q1 | 11.89 Million CNY | 9.36% |
| 2011 Q2 | 16 Million CNY | 34.56% |
| 2011 Q3 | 19.58 Million CNY | 22.33% |
| 2011 Q4 | 14.55 Million CNY | -25.66% |
| 2011 FY | 62.04 Million CNY | 61.19% |
| 2010 FY | 38.49 Million CNY | 27.76% |
| 2010 Q1 | 7.89 Million CNY | 0.0% |
| 2010 Q3 | 9.13 Million CNY | -13.61% |
| 2010 Q2 | 10.57 Million CNY | 33.95% |
| 2010 Q4 | 10.87 Million CNY | 19.03% |
| 2009 FY | 30.13 Million CNY | 18.23% |
| 2008 FY | 25.48 Million CNY | 56.2% |
| 2007 FY | 16.31 Million CNY | 0.0% |